Effects of bisphosphonate on the endochondral bone formation of the mandibular condyle.
The development of the mandibular condylar cartilage is important for the overall growth of the mandible. However, there have been a few researches into medical approaches aimed at controlling condylar growth. This study examined the effects of bisphosphonate on the growth of the condylar cartilage. Alendronate (3.5 mg/kg/week) was administered to postnatal day 1 SD rats for 7 and 10 days. The thickness of each chondrocyte layer and the level of MMP-9 expression were measured. The anteroposterior diameter of the developing condyle was unaffected by the alendronate treatment for 7 days (P > 0.05). The total thickness of the cartilage layers was also unaffected by the treatment for 7 days (P > 0.05). In particular, there was no change in the thickness of the perichondrium and reserve cell layer at the measured condylar regions (P > 0.05). However, the thickness of the proliferating cell layer was reduced significantly, whereas the thickness of hypertrophied cartilage layer was increased (P < 0.05). The number of chondroclasts engaged in hypertrophied cartilage resorption was reduced significantly by the alendronate treatment (P < 0.05). The level of MMP-9 expression was reduced at both the transcription and translation levels by the alendronate treatment for 7 and 10 days. These results indicate that alendronate (>3.5 mg/kg/week) inhibits the longitudinal growth of the mandibular condyle by inhibiting chondrocyte proliferation and the resorption of hypertrophied cartilage for ossification.
Kim
M S
MS
Dental Science Research Institute, 2nd stage Brain Korea, School of Dentistry, Chonnam National University, Gwangju, South Korea.
Jung
S Y
SY
Kang
J H
JH
Kim
H J
HJ
Ko
H M
HM
Jung
J Y
JY
Koh
J T
JT
Kim
W J
WJ
Kim
S M
SM
Lee
E J
EJ
Kim
S H
SH
D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001846:Bone Development / Q000187:drug effects*; D002358:Cartilage, Articular / Q000166:cytology; D004334:Drug Administration Schedule; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D008335:Mandibular Condyle / Q000187:drug effects* / Q000502:physiology; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D050071:Bone Density Conservation Agents; D020780:Matrix Metalloproteinase 9; D019386:Alendronate